Efficacy and safety of deferoxamine in moderately ill COVID-19 patients: An open label, randomized controlled trial.

Ali AmeriFarnaz PourseyediParivash DavoodianOmid SafaSoheil HassanipourMohammad Fathalipour

Published in: Medicine (2024)

Deferoxamine had no significant impact on improving moderately ill patients with COVID-19. However, it was well-tolerated in the patients, and this intervention demonstrated a safe profile of adverse events.

Keyphrases

randomized controlled trial
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
study protocol
sars cov
prognostic factors
patient reported outcomes